Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes: insurer competition and lower premiums, the wide variation in health care costs from place to place, and can precision medicine and pathways co-exist?
This article tackles the question of whether precision medicine and clinical pathways are compatible and argues that “not only are precision medicine and pathways compatible, but they are also similar and most certainly complementary, in some ways.”
Previous research reporting “no consistent relationship between cost and quality across the country” has relied solely on government data. So when a new study looked at information released from several private insurers, they were surprised to find that while costs still vary from place to place, “The most expensive places for Medicare are not the most expensive places for private insurers. In fact, there was essentially zero correlation between where a city ranks in Medicare spending and where it ranks in private-insurance spending—even when you only consider people undergoing the exact same procedure.”
This study of insurance participation and premiums found that “the addition of a single insurer in a county was associated with a 1.2 percent lower premium for the average silver plan and a 3.5 percent lower premium for the benchmark plan in the federally run Marketplaces.”
The articles above are from our dedicated Oncology Clinical Pathways e-magazine. Follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)